OraVescent meets Phase III primary endpoint

Cephalon (CEPH) said its OraVescent fentanyl met the primary endpoint of improvement on the sum of pain intensity difference (SPID) scale in a Phase III trial to treat breakthrough cancer pain (p<0.01...